Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 22, 2014, Pages 8179-8184

  Twu, Olivia ^a   Dessí, Daniele ^b   Vu, Anh ^a   Mercer, Frances ^a   Stevens, Grant C ^a   De Miguel, Natalia ^c   Rappelli, Paola ^b   Cocco, Anna Rita ^b   Clubb, Robert T ^a   Fiori, Pier Luigi ^b   Johnson, Patricia J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SASSARI   (Italy)

^c INSTITUTO DE INVESTIGACIONES BIOTECNOLÓGICAS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CD74 ANTIGEN; ENZYME; HUMAN MACROPHAGE MIGRATION INHIBITION FACTOR; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; PROTEIN KINASE B; TAUTOMERASE; TRICHOMONAS VAGINALIS MACROPHAGE MIGRATION INHIBITION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; MACROPHAGE MIGRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; RECEPTOR BINDING; TRICHOMONAS VAGINALIS;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELLS, CULTURED; CONSERVED SEQUENCE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MACROPHAGES; MALE; MAP KINASE SIGNALING SYSTEM; MOLECULAR SEQUENCE DATA; PROSTATE; PROSTATIC NEOPLASMS; PROTOZOAN PROTEINS; SEQUENCE HOMOLOGY; TRICHOMONAS INFECTIONS; TRICHOMONAS VAGINALIS;

EID: 84901820325     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1321884111     Document Type: Article

References (69)

1. Rigamonti N, Bellone M (2012) Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol Immunother 61(4):453-468.
2. Sutcliffe S, Platz EA (2008) Inflammation and prostate cancer: A focus on infections. Curr Urol Rep 9(3):243-249. (Pubitemid 351769010)
3. Vendramini-Costa DB, Carvalho JE (2012) Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 18(26):3831-3852.
4. World Health Organization (2012) Global incidence and prevalence of selected curable sexually transmitted infections - 2008 (WHO, Geneva).
5. Gardner WA, Jr., Culberson DE, Bennett BD (1986) Trichomonas vaginalis in the prostate gland. Arch Pathol Lab Med 110(5):430-432. (Pubitemid 16104279)
6. Mitteregger D, et al. (2012) High detection rate of Trichomonas vaginalis in benign hyperplastic prostatic tissue. Med Microbiol Immunol (Berl) 201(1):113-116.
7. Stark JR, et al. (2009) Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst 101(20):1406-1411.
8. Sutcliffe S, et al. (2006) Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(5):939-945. (Pubitemid 43823521)
9. Taylor ML, Mainous AG, 3rd, Wells BJ (2005) Prostate cancer and sexually transmitted diseases: A meta-analysis. Fam Med 37(7):506-512. (Pubitemid 40967713)
10. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL (2006) Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 177(12):8730-8739. (Pubitemid 44893839)
11. Meyer-Siegler KL, Leifheit EC, Vera PL (2004) Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 4:34.
12. Conroy H, Mawhinney L, Donnelly SC (2010) Inflammation and cancer: macrophage migration inhibitory factor (MIF) - The potential missing link. QJM 103(11):831-836.
13. Bucala R, Donnelly SC (2007) Macrophage migration inhibitory factor: A probable link between inflammation and cancer. Immunity 26(3):281-285. (Pubitemid 46413914)
14. Bernhagen J, et al. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365(6448):756-759. (Pubitemid 23339882)
15. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J (2002) Macrophage migration inhibitory factor (MIF): Mechanisms of action and role in disease. Microbes Infect 4(4): 449-460. (Pubitemid 34270682)
16. del Vecchio MT, et al. (2000) Macrophage migration inhibitory factor in prostatic adenocarcinoma: Correlation with tumor grading and combination endocrine treatment-related changes. Prostate 45(1):51-57.
17. Hussain F, et al. (2013) Human anti-macrophage migration inhibitory factor antibodies inhibit growth of human prostate cancer cells in vitro and in vivo. Mol Cancer Ther 12(7):1223-1234.
18. Meyer-Siegler KL, Iczkowski KA, Vera PL (2005) Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer 5:73.
19. Tawadros T, et al. (2013) Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. Endocr Relat Cancer 20(1):137-149.
20. Yu DS, Lin JC, Hsieh DS, Chang SY, Lee CF (2006) Modulation of MDR-1 gene by MIF and GSTpi with drug resistance generation in hormone independent prostate cancer. Arch Androl 52(4):283-291. (Pubitemid 44264741)
21. Meyer-Siegler KL, Bellino MA, Tannenbaum M (2002) Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 94(5):1449-1456. (Pubitemid 34212639)
22. Meyer-Siegler K, Hudson PB (1996) Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 48(3):448-452. (Pubitemid 26317487)
23. Meyer-Siegler KL, et al. (2007) Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun 8(8):646-652. (Pubitemid 350238434)
24. Agarwal R, et al. (2007) Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol 196(4):348.e1-5.
25. Fromont G, et al. (2012) Biological significance of perineural invasion (PNI) in prostate cancer. Prostate 72(5):542-548.
26. Mitchell RA, Metz CN, Peng T, Bucala R (1999) Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 274(25):18100-18106.
27. Leng L, et al. (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197(11):1467-1476. (Pubitemid 36686708)
28. Mitchell RA, et al. (2002) Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response. Proc Natl Acad Sci USA 99(1):345-350. (Pubitemid 34060365)
29. Calandra T, et al. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6(2):164-170. (Pubitemid 30082360)
30. Morand EF (2005) New therapeutic target in inflammatory disease: Macrophage migration inhibitory factor. Intern Med J 35(7):419-426.
31. Augustijn KD, et al. (2007) Functional characterization of the Plasmodium falciparum and P. berghei homologues of macrophage migration inhibitory factor. Infect Immun 75(3):1116-1128. (Pubitemid 46385802)
32. Falcone FH, et al. (2001) A Brugia malayi homolog of macrophage migration inhibitory factor reveals an important link between macrophages and eosinophil recruitment during nematode infection. J Immunol 167(9):5348-5354. (Pubitemid 33009774)
33. Kamir D, et al. (2008) A Leishmania ortholog of macrophage migration inhibitory factor modulates host macrophage responses. J Immunol 180(12):8250-8261.
34. Sommerville C, et al. (2013) Biochemical and immunological characterization of Toxoplasma gondii macrophage migration inhibitory factor. J Biol Chem 288(18): 12733-12741.
35. Rosengren E, et al. (1997) The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett 417(1):85-88. (Pubitemid 27490478)
36. Rosengren E, et al. (1996) The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 2(1):143-149.
37. Swope M, Sun HW, Blake PR, Lolis E (1998) Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J 17(13):3534-3541. (Pubitemid 28327372)
38. Hermanowski-Vosatka A, et al. (1999) Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry 38(39):12841-12849.
39. Bendrat K, et al. (1997) Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry 36(49):15356-15362. (Pubitemid 27528002)
40. Fingerle-Rowson G, et al. (2009) A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol Cell Biol 29(7):1922-1932.
41. Bloom BR, Bennett B (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153(3731):80-82.
42. Verjans E, et al. (2009) Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer 9:230.
43. Lue H, et al. (2007) Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26(35):5046-5059. (Pubitemid 47206949)
44. Datta SR, et al. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2):231-241. (Pubitemid 27456390)
45. Bifulco C, McDaniel K, Leng L, Bucala R (2008) Tumor growth-promoting properties of macrophage migration inhibitory factor. Curr Pharm Des 14(36):3790-3801.
46. Scherbakova EA, Stromskaya TP, Rybalkina EY, Kalita OV, Stavrovskaya AA (2008) Role of the PTEN protein in the multidrug resistance of prostate cancer cells. Mol Biol 42(3):430-435. (Pubitemid 351962273)
47. David JR (1966) Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56(1):72-77.
48. Cooke G, Armstrong ME, Donnelly SC (2009) Macrophage migration inhibitory factor (MIF), enzymatic activity and the inflammatory response. Biofactors 35(2):165-168.
49. Vanácová S, Yan W, Carlton JM, Johnson PJ (2005) Spliceosomal introns in the deep-branching eukaryote Trichomonas vaginalis. Proc Natl Acad Sci USA 102(12):4430-4435. (Pubitemid 40397129)
50. Abu-Shakra M, Buskila D, Shoenfeld Y (1999) Molecular mimicry between host and pathogen: Examples from parasites and implication. Immunol Lett 67(2):147-152. (Pubitemid 29191534)
51. Beswick EJ, Reyes VE (2008) Macrophage migration inhibitory factor and interleukin-8 produced by gastric epithelial cells during Helicobacter pylori exposure induce expression and activation of the epidermal growth factor receptor. Infect Immun 76(7): 3233-3240.
52. Gore Y, et al. (2008) Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 283(5):2784-2792.
53. Starlets D, et al. (2006) Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107(12):4807-4816. (Pubitemid 43882632)
54. Calandra T, Bucala R (1995-1996) Macrophage migration inhibitory factor: A counter-regulator of glucocorticoid action and critical mediator of septic shock. J Inflamm 47(1-2):39-51. (Pubitemid 26376200)
55. Oertelt-Prigione S (2012) Immunology and the menstrual cycle. Autoimmun Rev 11(6-7): A486-A492.
56. Madkan VK, Giancola AA, Sra KK, Tyring SK (2006) Sex differences in the transmission, prevention, and disease manifestations of sexually transmitted diseases. Arch Dermatol 142(3):365-370.
57. Baggiolini M, Clark-Lewis I (1992) Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 307(1):97-101.
58. Koch AE, et al. (1992) Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258(5089):1798-1801. (Pubitemid 23087348)
59. Botelho MC, Machado JC, Brindley PJ, Correia da Costa JM (2011) Targeting molecular signaling pathways of Schistosoma haemotobium infection in bladder cancer. Virulence 2(4):267-279.
60. Wroblewski LE, Peek RM, Jr., Wilson KT (2010) Helicobacter pylori and gastric cancer: Factors that modulate disease risk. Clin Microbiol Rev 23(4):713-739.
61. Porta C, Riboldi E, Sica A (2011) Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett 305(2):250-262.
62. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 30(7):1073-1081.
63. Clark CG, Diamond LS (2002) Methods for cultivation of luminal parasitic protists of clinical importance. Clin Microbiol Rev 15(3):329-341. (Pubitemid 34761343)
64. Dyall SD, et al. (2000) Presence of a member of the mitochondrial carrier family in hydrogenosomes: Conservation of membrane-targeting pathways between hydrogenosomes and mitochondria. Mol Cell Biol 20(7):2488-2497. (Pubitemid 30152056)
65. Delgadillo MG, Liston DR, Niazi K, Johnson PJ (1997) Transient and selectable transformation of the parasitic protist Trichomonas vaginalis. Proc Natl Acad Sci USA 94(9): 4716-4720. (Pubitemid 27194309)
66. Twu O, et al. (2013) Trichomonas vaginalis exosomes deliver cargo to host cells and mediate host. parasite interactions. PLoS Pathog 9(7):e1003482.
67. Lustig G, Ryan CM, Secor WE, Johnson PJ (2013) Trichomonas vaginalis contact-dependent cytolysis of epithelial cells. Infect Immun 81(5):1411-1419.
68. Mu Z, Hachem P, Pollack A (2005) Antisense Bcl-2 sensitizes prostate cancer cells to radiation. Prostate 65(4):331-340. (Pubitemid 41759965)
69. Addis MF, et al. (1999) Identification of Trichomonas vaginalis alpha-actinin as the most common immunogen recognized by sera of women exposed to the parasite. J Infect Dis 180(5):1727-1730. (Pubitemid 29506484)